Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Primary Lymphoid Organs01:16

Primary Lymphoid Organs

Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Systemic Therapy for Advanced-Stage Hodgkin Lymphoma.

Cancers·2026
Same author

Prevalence and perceptions of e-cigarette use in orthodontic patients: A cross-sectional survey.

Journal of orthodontics·2026
Same author

Gender- and age-specific patterns of tennis-related injuries in pediatric populations: Insights from emergency room data (2014-2023).

Injury·2026
Same author

Non-JAK-family gene fusions in cutaneous T-cell lymphoma highlights genetic diversity and potential therapeutic targets.

Haematologica·2026
Same author

Intracranial hemorrhage in patients with primary brain cancer receiving anticoagulation.

Blood vessels, thrombosis & hemostasis·2026
Same author

Early-Stage Hodgkin Lymphoma: Time for Novel Agents?

Hematology/oncology clinics of North America·2026
Same journal

Present and Emerging Strategies for Disease Assessment in Hodgkin Lymphoma.

Cancer journal (Sudbury, Mass.)·2026
Same journal

Nodular Lymphocyte-predominant Hodgkin Lymphoma: Incidence, Pathogenesis, Management.

Cancer journal (Sudbury, Mass.)·2026
Same journal

Management of Classic Hodgkin Lymphoma in Special Clinical Situations.

Cancer journal (Sudbury, Mass.)·2026
Same journal

Older Patients With Hodgkin Lymphoma: A Contemporary Review.

Cancer journal (Sudbury, Mass.)·2026
Same journal

Adolescent and Young Adult Patients With Classical Hodgkin Lymphoma: A Review as a Case Study in AYA Cancer Care.

Cancer journal (Sudbury, Mass.)·2026
Same journal

Hodgkin Lymphoma: Management of Patients Who Fail Primary Therapy.

Cancer journal (Sudbury, Mass.)·2026
See all related articles

Related Experiment Video

Updated: May 23, 2026

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
08:53

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

Early-Stage Hodgkin Lymphoma.

Kishan Patel1, Varun Iyengar, Alison Moskowitz

  • 1Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY.

Cancer Journal (Sudbury, Mass.)
|May 21, 2026
PubMed
Summary
This summary is machine-generated.

Combined modality therapy (CMT) offers high cure rates for early-stage Hodgkin lymphoma but causes significant toxicity. Novel strategies, including response-adapted treatments and new therapies like brentuximab vedotin, aim to maintain survival while reducing complications.

Keywords:
Hodgkin lymphomaearly-stagefavorableunfavorable

More Related Videos

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Related Experiment Videos

Last Updated: May 23, 2026

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
08:53

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma
10:52

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Area of Science:

  • Oncology
  • Hematology
  • Clinical Trials

Background:

  • Combined modality therapy (CMT) is standard for early-stage Hodgkin lymphoma (HL), yielding excellent survival rates.
  • However, CMT poses significant long-term toxicity risks for a predominantly young patient population.
  • This necessitates the development of less toxic, yet equally effective, treatment strategies.

Purpose of the Study:

  • To review the historical management of early-stage Hodgkin lymphoma.
  • To discuss novel therapeutic approaches aimed at reducing treatment-related toxicity.
  • To explore ongoing studies that may redefine the standard of care for early-stage HL.

Main Methods:

  • Review of historical treatment data for early-stage Hodgkin lymphoma.
  • Analysis of current research incorporating response-adapted therapy based on interim FDG-PET/CT scans.
  • Evaluation of novel agents, including brentuximab vedotin and immune checkpoint inhibitors.

Main Results:

  • CMT has established high cure rates but is associated with considerable long-term adverse effects.
  • Response-adapted strategies and novel therapies show promise in maintaining efficacy while mitigating toxicity.
  • Ongoing clinical trials are investigating these innovative approaches for HL management.

Conclusions:

  • There is a critical need to balance high cure rates with reduced long-term toxicity in early-stage HL.
  • Novel treatment strategies, including FDG-PET/CT-guided therapy and targeted agents like brentuximab vedotin, represent the future of HL management.
  • Further research and clinical trials are essential to optimize treatment paradigms and improve patient outcomes.